Research programme: calcium channel and sodium channel antagonists - Anabios Corporation

Drug Profile

Research programme: calcium channel and sodium channel antagonists - Anabios Corporation

Alternative Names: N-type CCB; N/T-Type CCB; NP-A; T-type CCB; Z-212

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator Neuromed Pharmaceuticals
  • Developer Hydra Biosciences; Neuromed Pharmaceuticals
  • Class Analgesics; Small molecules
  • Mechanism of Action N type calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 15 Jul 2014 Zalicus has merged with EPIRUS Biopharmaceuticals
  • 18 Jun 2014 Sodium channel modulator programme licensed to AnaBios Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top